Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y. Westhovens R, et al. Rheumatology (Oxford). 2006 Oct;45(10):1238-46. doi: 10.1093/rheumatology/kel066. Epub 2006 Mar 27. Rheumatology (Oxford). 2006. PMID: 16567357 Clinical Trial.
Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology. International League of Associations for Rheumatology.
Wells G, Boers M, Shea B, Tugwell P, Westhovens R, Saurez-Almazor M, Buchbinder R. Wells G, et al. Among authors: westhovens r. J Rheumatol. 1999 Jan;26(1):217-21. J Rheumatol. 1999. PMID: 9918267 Clinical Trial.
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.
Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. Merrill JT, et al. Among authors: westhovens r. Arthritis Rheum. 2010 Oct;62(10):3077-87. doi: 10.1002/art.27601. Arthritis Rheum. 2010. PMID: 20533545 Free article. Clinical Trial.
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R. Durez P, et al. Among authors: westhovens r. Rheumatology (Oxford). 2005 Apr;44(4):465-8. doi: 10.1093/rheumatology/keh494. Epub 2005 Feb 3. Rheumatology (Oxford). 2005. PMID: 15695306
387 results